# Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

> **NCT04888507** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** Pozelimab
- **DRUG:** Cemdisiran

## Key facts

- **NCT ID:** NCT04888507
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2022-05-05
- **Final completion:** 2023-05-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888507, "Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04888507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*